Miri Blank

Miri Blank

Auto-generated profile, based on publicly available information

Miri Blank

Sheba Med Ctr, Zabludowicz Ctr Autoimmune Dis, Ramat Gan, Israel

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008
Verified
Journal Article
Closed access
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
GZGisele Zandman-Goddard
Gisele Zandman-Goddard
LSLjudmila Stojanovich
Ljudmila Stojanovich
MCMaurizio Cutolo
Maurizio Cutolo
HAHoward Amital
Howard Amital
YSYaniv Sherer
Yaniv Sherer

1 January 2008
Verified
Journal Article
Closed access
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
MBMiri Blank
Miri Blank
AAAbu-Shakra Abu-Shakra
Abu-Shakra Abu-Shakra
HAHoward Amital
Howard Amital
OBOri Barzilai
Ori Barzilai
MGM Eric Gershwin
M Eric Gershwin

1 January 2008
Verified
Journal Article
Closed access
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
BGBoris Gilburd
Boris Gilburd
MAMahmud Abu-Shakra
Mahmud Abu-Shakra
HAHoward Amital
Howard Amital
OBOri Barzilai
Ori Barzilai
YTYaron Tomer
Yaron Tomer

1 July 2004
Verified
Journal Article
Closed access
YSYehuda Shoenfeld
Yehuda Shoenfeld
SLShaul Lev
Shaul Lev
IBIlan Blatt
Ilan Blatt
MBMiri Blank
Miri Blank
JFJoseph Font
Joseph Font
JDJan Damoiseaux
Jan Damoiseaux

26 December 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Dana Ben-Ami ShorDana Ben-Ami Shor
Dana Ben-Ami Shor
JLJordan Lachnish
Jordan Lachnish
TBTomer Bashi
Tomer Bashi
Shani DahanShani Dahan
Shani Dahan
ASAsaf Shemer
Asaf Shemer
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
Helminths or their products can immunomodulate the host immune system, and this phenomenon may be applied as the basis of new anti-inflammatory treatments. Previously, we have shown the efficacy of tuftsin–phosphorylcholine (TPC), based on a helminth product, in four animal models of autoimmune diseases: arthritis, colitis, systemic lupus erythematosus, and experimental autoimmune encephalomyelitis. We demonstrated that TPC reduced inflammatory process ex vivo in peripheral blood lymphocytes (PBLs) and in biopsies from giant-cell arteritis. In the present study, we assessed the therapeutic potential of TPC treatment on a chronic colitis murine model. C57BL/6 mice with chronic colitis were treated with TPC after the third cycle of 2% dextran sodium sulfate (DSS). Oral TPC treatment resulted in amelioration of the colitis clinical manifestations exemplified by reduced disease activity index (DAI) score, expansion of mesenteric lymph nodes (MLN) T regulatory cells (shown by Fluorescence Activated Cell Sorting (FACS)), significant reduction in the expression of pro-inflammatory cytokines (IL-1β, IL17, IL-6, TNFα), and elevation in the expression of anti-inflammatory cytokine IL-10 (shown by RT-PCR). This study demonstrated the potential immunomodulatory effects of oral administration of TPC in a chronic colitis murine model. Further clinical trials are needed in order to evaluate this novel approach for the treatment of patients with inflammatory bowel disease.

4 April 2013 in BMC Medicine
Verified
Journal Article
Open access
PDF file
AKAviva Katzav
Aviva Katzav
NGNikolaos Grigoriadis
Nikolaos Grigoriadis
TETania Ebert
Tania Ebert
OTOlga Touloumi
Olga Touloumi
MBMiri Blank
Miri Blank
JCJoab Chapman
Joab Chapman
We investigated interactions between genetically and autoimmune-mediated coagulopathies by inducing experimental antiphospholipid syndrome (eAPS) in mice carrying the factor V Leiden (FVL) mutation.